MediciNova receives notice of allowance for new MN-001/002 patent in Japan

MediciNova announced that it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-001, or tipelukast, and MN-002 for the treatment of “fibrosis” which includes a broad range of fibrosis / fibrotic disease in different organs due to different causes. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than June 2035. The allowed claims cover a composition for inhibiting or treating fibrosis using MN-001 or MN-002. The allowed claims cover oral administration including liquid and solid dosage forms.
https://thefly.com/landingPageNews.php?id=2845049